Cannabis, CBD & Hemp



FinCanna Capital Corp.
Latest Comments
image_pdfimage_print

XPhyto Therapeutics Hugh Rogers talks about rapid-results virus testing

InvestorIntel’s Peter Clausi talks with Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. (CSE: XPHY | OTCQB: XPHYF) about […]


FinCanna Capital’s CEO on being the only pure royalty company in the cannabis industry

InvestorIntel’s Tracy Weslosky spoke with Andriyko Herchak, CEO of FinCanna Capital Corp. (CSE: CALI | OTCQB: FNNZF), about FinCanna’s cannabis […]


XPhyto Therapeutics moving forward from successful prototype testing of saliva virus test

Non-invasive test can detect viral RNA in asymptomatic patients XPhyto Therapeutics Corp. (CSE: XPHY | OTCQB: XPHYF | FSE: 4XT) […]


Red Light Holland enters the market of legal magic truffles

Exploring the recreational and potential medical use of psychedelics Most people have heard of ‘magic mushrooms’, but they may be […]


Red Light Holland’s Todd Shapiro on investing in a medical and scientific division for the understanding of medical psychedelics

“We have named a Science and Innovation division called Scarlette Lillie… We thought that this is a way to show […]


Drolet Stock Note: XPhyto Therapeutics — Medical Cannabis Meets Modern Sciences

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released his Stock Notes on XPhyto Therapeutics Corp. (CSE: XPHY) for […]


FinCanna Capital looks set to benefit from their cannabis royalty portfolio after a win-win deal with QVI Inc.

The latest good news announced this month is that  FinCanna Capital Corp. (CSE: CALI | OTCQB: FNNZF) (“FinCanna”) has restructured […]


FinCanna Capital Corp.